Pediatric epilepsy syndromes, such as Dravet Syndrome and Lennox-Gastaut Syndrome, are devastating neurological conditions with limited treatment options and a high burden on families. Remi Therapeutics saw an opportunity to address this gap through a precision-medicine approach targeting a novel ion channel pathway.
Traditional antiepileptic drugs (AEDs) often fail in rare epilepsy due to genetic variability and treatment resistance. The urgent need for safer, more effective options prompted Remi to pursue a first-in-class candidate capable of addressing the root neurological dysfunctions in these disorders.
Through a combination of in-house screening and academic collaboration, Remi identified a compound that modulates a specific sodium ion channel implicated in seizure activity. The drug demonstrated strong results in zebrafish and rodent models of genetic epilepsy, significantly reducing seizure frequency and duration.
Remi secured FDA Orphan Drug Designation early in the process, allowing for regulatory incentives and fast-track support. Clinical development was strategically staged, with adaptive trial designs enabling real-time modifications based on efficacy signals.
Phase 1 data showed a favorable safety profile, while Phase 2 trials demonstrated a 65% reduction in seizure frequency in treatment-resistant patients. Parents reported improvements in behavior, alertness, and daily functioning, pointing to enhanced quality of life.
Remi’s work in pediatric epilepsy not only opened new treatment possibilities for a previously underserved population but also exemplified the company’s commitment to bold, mission-driven innovation. The case has become a flagship example of Remi’s ability to unlock asymmetric value for both patients and stakeholders.
We have a wide range of solutions to help you succeed.
